LimmaTech Biologics develops vaccines using a proprietary self-adjuvanting and multi-antigen platform aimed at combating the global antimicrobial resistance epidemic. The company is advancing disease-specific programs targeting Staphylococcus aureus, Shigella and sexually transmitted infections such as gonorrhea. Headquartered in Schlieren, Switzerland, LimmaTech plans to use Series A proceeds to accelerate both preclinical and clinical development. Its stated 2024 priorities include initiating a Phase 1 trial for the Staphylococcus aureus candidate and a Phase 2 trial for the Shigella candidate. The funding will also support further development of the core platform alongside additional vaccine approaches. To date the company has raised a total of USD 40 million in Series A financing. LimmaTech Biologics is developing next‑generation vaccines to prevent life‑threatening bacterial infections driven by antimicrobial resistance, using proprietary E. coli expression‑based technology. Its platform produces multivalent vaccines that combine carbohydrate and protein antigens and is being applied to programs addressing shigellosis and gonorrhea. The company is advancing both preclinical and clinical candidates and has a later‑stage focus on a Shigella vaccine program that was developed in collaboration with GSK and recently exclusively in‑licensed. LimmaTech expects preliminary Phase 2 results from the Shigella program in the second half of 2023. The company recently appointed Dr. Franz‑Werner Haas as CEO and is expanding its board with investor representatives as it scales its pipeline. The $37 million Series A will fund advancement of the platform and acceleration of preclinical and clinical programs.

Total raised

$39M

Funding rounds

2

Latest round

Series A

Latest activity

Feb 2024